Document is current
Any future updates will be listed below
-
Authors
Desharnais, Lysanne
Sorin, Mark
Rezanejad, Morteza
Liu, Bridget
Karimi, Elham
Atallah, Aline https://orcid.org/0000-0001-7256-9632
Swaby, Anikka M. https://orcid.org/0000-0002-9946-3587
Yu, Miranda W. https://orcid.org/0000-0003-3902-0124
Doré, Samuel
Hartner, Saskia https://orcid.org/0009-0006-1030-1191
Fiset, Benoit
Wei, Yuhong
Kadang, Baharak
Rayes, Roni
Joubert, Philippe
Camilleri-Broët, Sophie https://orcid.org/0000-0002-3453-636X
Fiset, Pierre-Olivier
Quail, Daniela F.
Spicer, Jonathan D. https://orcid.org/0000-0003-2708-1309
Walsh, Logan A. https://orcid.org/0000-0001-8771-2577
- License Information
-
More Information
Article History
Received: 20 September 2024
Accepted: 20 January 2025
First Online: 4 February 2025
Competing interests
: J.D.S. - Consulting, advisory role or honoraria: AstraZeneca, Merck, Roche, BMS, Novartis, Chemocentryx, Amgen, Protalix Biotherapeutics, Xenetic Biosciences, Regeneron, Eisai, Peerview, OncLive, Medscape, Pfizer. Grant to institution: AstraZeneca, BMS, Merck, Roche, CLS Therapeutics, Protalix Biotherapeutics, Pfizer, Regeneron. Clinical trial leadership role: BMS, Novartis, Roche, Merck, AstraZeneca. POF has participated in paid consulting services with Amgen, Astellas, AstraZeneca, Boehringer Ingelheim, Bristol Meyers Squibb, EMD Serono, Incyte, Merck, Novartis, Pfizer, Precision Rx-Dx and Roche. He has received research support from Astellas, AstraZeneca, Bristol Meyers Squibb and Merck. The remaining authors declare no competing interests.
